Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PPD Continues High-speed Expansion In Asia

This article was originally published in The Pink Sheet Daily

Executive Summary

U.S.-based CRO makes its second acquisition this quarter of a Chinese CRO.

You may also be interested in...

Global Financial Crisis Could Speed Up Sending Pharma Research To China

BEIJING - The financial crisis ricocheting across the United States and Europe could cut into R&D funding by the globe's top pharmaceutical powers, but is also likely to trigger sending more drug research to Chinese scientists, according to industry insiders and analysts

Excel PharmaStudies Chairman Mark Engel On China’s Rapidly Expanding Clinical Trials: An Interview With PharmAsia News (Part 1 of 2)

BEIJING - Excel PharmaStudies, established in 2000, is one of the leading clinical research organizations in China. Excel PharmaStudies Chairman Mark Engel recently talked with PharmAsia News' Beijing bureau about the high-speed development of China's pharmaceutical market and the role of clinical trials in China. Engel also outlined challenges, solutions and opportunities regarding clinical trials in China.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts